A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2018
At a glance
- Drugs CT 1812 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- Sponsors Cognition Therapeutics
- 16 Apr 2018 Status changed from planning to not yet recruiting.
- 26 Oct 2017 New trial record